Comparative Pharmacology
Head-to-head clinical analysis: TETRACHEL versus VIBRAMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TETRACHEL versus VIBRAMYCIN.
TETRACHEL vs VIBRAMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing addition of amino acids to the growing peptide chain. Bacteriostatic.
500 mg orally once daily for 28 days; for severe infections, 500 mg twice daily for 14 days.
100 mg orally or intravenously every 12 hours on day 1, then 100 mg once daily; severe infections: 100 mg every 12 hours.
None Documented
None Documented
6-11 hours (prolonged in renal impairment; up to 57 hours in anuria).
Terminal elimination half-life is 16-18 hours in patients with normal renal function. Prolonged to 20-36 hours in severe renal impairment; no significant change in hepatic impairment.
Renal 60% (glomerular filtration), fecal 40% (biliary excretion of active drug and metabolites).
Approximately 40% excreted unchanged in urine via glomerular filtration; 20-25% eliminated in feces via biliary secretion; remainder metabolized. Renal clearance is about 30 mL/min.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic